I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib ove..:
Bi, Jianling
;
Dixit, Garima
;
Zhang, Yuping
...
Pharmaceuticals. 14 (2021) 7 - p. 682 , 2021
Link:
https://doi.org/10.3390/ph14070682
RT Journal T1
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
UL https://suche.suub.uni-bremen.de/peid=cr-10.3390_ph14070682&Exemplar=1&LAN=DE A1 Bi, Jianling A1 Dixit, Garima A1 Zhang, Yuping A1 Devor, Eric A1 Losh, Haley A1 Newtson, Andreea A1 Coleman, Kristen A1 Santillan, Donna A1 Maretzky, Thorsten A1 Thiel, Kristina A1 Leslie, Kimberly PB MDPI AG YR 2021 SN 1424-8247 JF Pharmaceuticals VO 14 IS 7 SP 682 LK http://dx.doi.org/https://doi.org/10.3390/ph14070682 DO https://doi.org/10.3390/ph14070682 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)